Lenalidomide Rafarm (Lenalidomide)

Lenalidomide is indicated for hematologic malignancies and related disorders.

• Multiple Myeloma: improves progression‑free survival and overall response in patients with relapsed or refractory disease.
• Myelodysplastic Syndromes: reduces transfusion dependence and delays transformation to acute leukemia in patients with del(5q) cytogenetic abnormality.
• Mantle Cell Lymphoma: contributes to disease control in patients who have received prior therapies.

• Lenalidomide binds to the cereblon component of the CRL4 E3 ubiquitin ligase complex, altering substrate specificity and leading to degradation of transcription factors Ikaros and Aiolos. This modulation reduces pro‑inflammatory cytokine production, inhibits angiogenesis, and promotes apoptosis of malignant plasma cells, thereby exerting antitumor activity in hematologic cancers.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may require fluid replacement.
• Nausea: feeling of sickness often accompanied by vomiting.
• Rash: mild skin eruptions or itching.
• Neutropenia: reduced neutrophil count increasing infection risk.

Serious or Rare Side Effects

• Thromboembolism: blood clots in veins or arteries that can be life‑threatening.
• Severe neutropenia or leukopenia: markedly low white blood cell counts.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.
• Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

Before initiating Lenalidomide therapy, several precautions should be considered.

• Pregnancy risk: contraindicated in pregnancy (Category X); effective contraception required.
• Thrombotic risk: assess patient history and consider prophylactic anticoagulation.
• Renal function: dose may need adjustment in patients with impaired kidney function.
• Hepatic function: monitor liver enzymes in patients with liver disease.
• Infection monitoring: watch for signs of infection due to neutropenia.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Lenalidomide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma concentrations.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): increased risk of bleeding.
• Immunosuppressants (e.g., cyclosporine): heightened risk of severe neutropenia.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase lenalidomide exposure.
• Vaccines: live attenuated vaccines may be less effective; avoid during treatment.
• NSAIDs: may exacerbate thrombosis risk when combined with lenalidomide.